Multifunctional protease inhibitors and their use in treatment of disease

• US 7,709,446 B2
• Filed: 07/20/2007
• Issued: 05/04/2010
• Est. Priority Date: 12/18/2000
• Status: Expired due to Fees

• Current Assignee: Arriva Pharmaceuticals, Inc.
• Original Assignee: Arriva Pharmaceuticals, Inc.
• Inventors: Pemberton, Philip A., Barr, Philip J., Gibson, Helen L.
• Primary Examiner(s): PROUTY, REBECCA E
• Application Number:
  US11/781,152
• Publication Number:
  US 20080085854A1
• Time in Patent Office: 1,019 Days
• Field of Search: None
• US Class Current: 514/20.2
• CPC Class Codes: C07K 14/811 Serine protease (E.C. 3.4.21) inhibitors
• CPC Class Codes: C07K 14/8125 Alpha-1-antitrypsin
• CPC Class Codes: C07K 14/8146 Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.

Claims

1. A protein conjugate comprising a) a first polypeptide comprising amino acids from about 1 to about 394 of SEQ ID NO:

2; and

b) a second polypeptide comprising amino acids from about 1 to 127 of SEQ ID NO;

6, wherein the first polypeptide is covalently linked to the second polypeptide through a disulfide bond between amino acid 127 of SEQ ID NO;

6 and a free cysteine residue of the SEQ ID NO;

2.

4. A pharmaceutical composition comprising the protein conjugate of claim 1, or the fusion protein of claim 2 or 3 admixed with a pharmaceutically acceptable vehicle.

5. A method for inhibiting protease activity, comprising contacting the protease with the protein conjugate of claim 1.

6. The method of claim 5 wherein the protease activity is associated with a disorder selected from the group consisting of emphysema, asthma, chronic obstructive pulmonary disease, cystic fibrosis, otitis media, and otitis extema.

7. The method of claim 5, wherein the protease activity is associated with HIV infection.

8. The method of claim 5, wherein the protein conjugate is contacted with the protease by administering the protein conjugate to an individual having the protease.

9. A method of treating an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity comprising administering to the individual an effective amount of the protein conjugate of claim 1.

10. The method of claim 9, wherein the individual suffers from emphysema.

11. The method of claim 9, wherein the individual suffers from asthma.

12. The method of claim 9, wherein the individual suffers from chronic obstructive pulmonary disease.

13. The method of claim 9, wherein the individual suffers from cystic fibrosis.

14. The method of claim 9, wherein the individual suffers from otitis media or otitis externa.

2. A fusion protein comprising SEQ ID NO:

18.

15. A method for inhibiting protease activity, comprising contacting the protease with the fusion protein of claims 2 or 3.

16. The method of claim 15 wherein the protease activity is associated with a disorder selected from the group consisting of emphysema, asthma, chronic obstructive pulmonary disease, cystic fibrosis, otitis media, and otitis extema.

17. The method of claim 16 wherein the disorder is emphysema.

18. The method of claim 16 wherein the disorder is asthma.

19. The method of claim 16 wherein the disorder is chronic obstructive pulmonary disease.

3. A fusion protein comprising SEQ ID NO:

20.